As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

U.S. regulators are reexamining infant RSV antibody treatments as safety questions surface, prompting new FDA scrutiny of ...

FDA reexamine infant RSV therapies with Sanofi, AstraZeneca, and Merck amid safety concerns and data review under new FDA leadership.

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

The US Food and Drug Administration is taking a closer look at RSV shots for infants as Health and Human Services Secretary Robert F. Kennedy Jr. continues to push for changes to the country’s ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Merck ...